glp 1 for chronic inflammation GLP-1 drugs calm beyond diabetes and weight loss GLP-1 receptor agonists as promising

Get medical advice from a healthcare professional first

doi: 10.1021/acs.jafc.7b00899 42

Laws vary by jurisdiction and individual circumstances

From topical research: Most commonly reported observation: mild transient redness at application site (attributed to vascular activity from VEGF stimulation) No systemic adverse events reported in human topical studies at standard concentrations No evidence of carcinogenicity or mutagenicity in available in vitro models From injectable research (preclinical): At supratherapeutic doses in animal models, mild injection site reactions have been noted No organ toxicity observed in standard preclinical safety panels No immunogenicity concerns identified (consistent with its endogenous structure) Copper considerations: GHK-Cu delivers a small amount of bioavailable copper

D.AckermanR